Alnylam Pharmaceuticals Liabilities related to the sale of future royalties and development funding increased by 3.4% to $227.49M in Q1 2026 compared to the prior quarter.
current_liabilities_royalty_and_development_funding_liab_f975f6| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $113.02M | $220.07M | $227.49M |
| QoQ Change | — | +94.7% | +3.4% |
| YoY Change | — | +94.7% | — |
| Segment | Q4 '25 | Q1 '26 |
|---|---|---|
| Vutrisiran | $94.50M | $98.50M |
| Zilebesrian | $6.80M | $7.50M |
| Total | $220.07M | $227.49M |